2025-522953-21-00招募中1 期
A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.3 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年3月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor2024-514532-24-00Boehringer Ingelheim International GmbH33
招募中
2 期
A Clinical Trial for Patients with Advanced Cancers2024-515020-36-00Corbus Pharmaceuticals Inc.108
招募中
不适用
A study in people with advanced cancer to test how well different doses of BI 770371 alone or in combination with ezabenlimab are toleratedjRCT2031220031Nippon Boehringer Ingelheim Co., Ltd12
招募中
1 期
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helpsMelanoma2025-522045-21-00Boehringer Ingelheim International GmbH13
招募中
3 期
A real-world study on how well ribociclib and hormone therapy work together to prevent early breast cancer from coming back.CTRI/2025/08/092443Novartis Healthcare Pvt Ltd3,100